Catalys Pacific
Catalys Pacific is a venture capital firm focused on creating and developing bespoke biotech companies through transpacific partnerships. With a strong presence in both Japan and the United States, the firm leverages its extensive global network and local expertise to access differentiated sourcing and early-stage investment opportunities. Catalys Pacific is dedicated to improving patient lives worldwide by driving innovation in healthcare and contributing to advancements in life sciences.
Catalys Pacific
AUSPICE OMOTESANDO 4F, 8-14, Minami-Aoyama 3-chome, Minato-ku, Tokyo 107-0062, Japan
Portfolio
Focused on developing novel therapies for hypertension, Mineralys aims to change the way hypertension is diagnosed, managed, and treated.
#Biopharmaceuticals
Committed to developing innovative therapeutics for renal disease, focusing on sparsentan for IgA nephropathy.
#Biopharmaceuticals
Developing advanced therapeutics for end-stage kidney disease, with a focus on upacicalcet for secondary hyperparathyroidism.
#Biopharmaceuticals
Focused on CNS therapeutic innovations, Aculys addresses the drug lag in Japan for approved medicines abroad.
#Biopharmaceuticals
Focused on liver disease therapeutics, Hepalys addresses the drug lag for innovative medicines in Japan.
#Biopharmaceuticals
A multi-asset precision oncology company focused on CDK7 inhibitors for cancer treatment.
#Precision Oncology
Exploring autoimmune mechanisms to develop precision medicines for neuropsychiatric diseases.
#Biotechnology
Focused on novel treatments for gastrointestinal diseases, advancing vonoprazan for acid-related disorders.
#Biopharmaceuticals
Key People
Founder, Managing Director
Managing Director
Venture Partner
Operating Partner
Operating Partner
Advisor